SARMs

Selective Androgen Receptor Modulators (SARMs) are a class of compounds that selectively activate the androgen receptor (AR) in a tissue-specific manner. By doing so, they offer the potential for therapeutic benefits with reduced side effects compared to traditional androgenic compounds [1]. SARMs have gained attention in recent years due to their ability to elicit beneficial anabolic effects while avoiding many of the unwanted side effects associated with steroidal agents [2].

SARMs have been proposed as potential treatments for various diseases, including muscle wasting, breast cancer, osteoporosis, and hypogonadism [1,3,4]. In addition, SARMs have been shown to stimulate AR-mediated gene expression and promote anabolic effects in muscle and bone [9].

Read our SARMs beginners guide and check out the published SARMs articles and research below.

Andarine
Cardarine
LGD 3033
LGD 4033
MK 677
Ostarine
RAD 140
S23
SR9009
YK11

References:

  1. Narayanan, R., Coss, C., Dalton, J. (2018). Development Of Selective Androgen Receptor Modulators (Sarms). Molecular and Cellular Endocrinology, (465), 134-142.
  2. Dodson, S., Baracos, V., Jatoi, A., Evans, W., Cella, D., Dalton, J., … & Steiner, M. (2011). Muscle Wasting In Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annu. Rev. Med., 1(62), 265-279.
  3. Solomon, Z., Mirabal, J., Mazur, D., Kohn, T., Lipshultz, L., Pastuszak, A. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews, 1(7), 84-94.
  4. Bhasin, S., Jasuja, R. (2009). Selective Androgen Receptor Modulators As Function Promoting Therapies. Current Opinion in Clinical Nutrition and Metabolic Care, 3(12), 232-240.
  5. Dalton, J., Barnette, K., Bohl, C., Hancock, M., Rodriguez, D., Dodson, S., … & Steiner, M. (2011). The Selective Androgen Receptor Modulator Gtx‐024 (Enobosarm) Improves Lean Body Mass and Physical Function In Healthy Elderly Men And Postmenopausal Women: Results Of A Double‐blind, Placebo‐controlled Phase II Trial. J cachexia sarcopenia muscle, 3(2), 153-161.
  6. Mohler, M., Bohl, C., Jones, A., Coss, C., Narayanan, R., He, Y., … & Miller, D. (2009). Nonsteroidal Selective Androgen Receptor Modulators (Sarms): Dissociating the Anabolic And Androgenic Activities Of The Androgen Receptor For Therapeutic Benefit. J. Med. Chem., 12(52), 3597-3617.
  7. Panneerselvam, P., Singh, L., Selvarajan, V., Chng, W., Ng, S., Tan, N., … & Ding, J. (2012). T-cell Death Following Immune Activation Is Mediated By Mitochondria-localized Sarm. Cell Death Differ, 3(20), 478-489.
  8. Peng, J., Yuan, Q., Lin, B., Panneerselvam, P., Wang, X., Luan, X., … & Ding, J. (2010). Sarm Inhibits Both Trif- and Myd88-mediated Ap-1 Activation. Eur. J. Immunol., 6(40), 1738-1747.
  9. Yin, D., Gao, W., Kearbey, J., Xu, H., Chung, K., He, Y., … & Dalton, J. (2002). Pharmacodynamics Of Selective Androgen Receptor Modulators. J Pharmacol Exp Ther, 3(304), 1334-1340.

Disclaimer

All content is to be used for informational purposes only. Do not substitute anything you read here for medical advice. See disclaimers.

© 2021 Sarms.io – All Rights Reserved

Links
Socials
Sarms.io
Logo